Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01135472 · ClinicalTrials.gov registry record · Phase 1
Plasm Gastrin Concentrations in Response to Nexium Administration in Healthy Volunteers
A Phase 1 study, sponsored by City of Hope Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT01135472 is a Phase 1 study that has completed, run by City of Hope Medical Center. The registered enrollment target is 10 participants.
The verdict
NCT01135472, a Phase 1 study, has completed, sponsored by City of Hope Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
This dose response study is proposed to explore the extent to which Nexium increases endogenous gastrin concentrations and to assess whether Nexium treatment may be useful in the setting of islet cell transplantation for type 1 diabetes to expand islet cells in vivo after transplant.
Interventions
- DRUG Esomeprazole Magnesium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2010-03 |
| Est. Completion | 2012-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01135472
The ClinicalTrials.gov registry entry for NCT01135472 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Esomeprazole Magnesium is the first listed.
NCT01135472 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01135472 about?
NCT01135472 is a clinical study titled "Plasm Gastrin Concentrations in Response to Nexium Administration in Healthy Volunteers". This dose response study is proposed to explore the extent to which Nexium increases endogenous gastrin concentrations and to assess whether Nexium treatment may be useful in the setting of islet cell transplantation for type 1 diabetes to expand islet cells in vivo after transplant.
What is the current status of trial NCT01135472?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2010-03. Estimated completion is 2012-04.
What interventions are being tested in trial NCT01135472?
The interventions under investigation include: Esomeprazole Magnesium (DRUG).
Who is sponsoring clinical trial NCT01135472?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.